Sonnet BioTherapeutics, Inc.: Sonnet BioTherapeutics Announces FDA Clearance of Its IND for SON-1010 for the Treatment of Advanced Solid Tumors
Represents Sonnet's first IND clearedPhase 1 trial initiation expected in 2Q22PRINCETON, NJ / ACCESSWIRE / March 16, 2022 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company")
Michaelv Morabito Pankaj Mohan Richard Kenney Exchange Commission Company Investigational New Drug Sonnet Biotherapeutics Inc
Source: finanznachrichten.de